Received: 22 October 2021
Accepted: 20 July 2022
First Online: 29 July 2022
: This review paper did not require IRB approvals and involved no patients.
: Not applicable.
: The corresponding author (Edward K Rodriguez) is an associate editor of BMC Musculoskeletal Disorder. EKR, AN, and MWG are co-inventors on a patent application submitted to the USPTO on the use of human relaxin-2 as a treatment for arthrofibrosis. The patent application is available for licensing.